

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 January 2024 (25.01.2024)



(10) International Publication Number
WO 2024/020083 A2

- (51) **International Patent Classification:**
C07K 14/705 (2006.01) *A61K 38/16* (2006.01)
- (21) **International Application Number:**
PCT/US2023/028123
- (22) **International Filing Date:**
19 July 2023 (19.07.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/390,780 20 July 2022 (20.07.2022) US
- (71) **Applicant: BIOCRYST PHARMACEUTICALS, INC.**
[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC 27703 (US).
- (72) **Inventors: BABU, Yarlagadda, S.;** 4836 Southlake Parkway, Birmingham, AL 35244 (US). **CHEN, Xilin;** 1695 Ridge Haven Run, Alpharetta, GA 30022 (US).
- (74) **Agent: GORDON, Dana, M. et al.;** Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) **Title:** FUSION PROTEIN INHIBITORS OF KLK5

(57) **Abstract:** Disclosed are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.

WO 2024/020083 A2